StockNews.com Upgrades Repligen (NASDAQ:RGEN) to Hold

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a report released on Wednesday.

A number of other research firms have also recently weighed in on RGEN. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. UBS Group cut their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Wells Fargo & Company began coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

Shares of RGEN stock opened at $124.73 on Wednesday. The stock has a fifty day moving average price of $141.54 and a 200 day moving average price of $144.77. The stock has a market cap of $6.99 billion, a PE ratio of -337.10, a P/E/G ratio of 4.36 and a beta of 0.96. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.23 earnings per share. Sell-side analysts forecast that Repligen will post 1.44 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Andra AP fonden acquired a new stake in Repligen during the second quarter worth about $25,000. Lazard Asset Management LLC increased its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the last quarter. UMB Bank n.a. increased its stake in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Blue Trust Inc. increased its stake in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the last quarter. Finally, Resources Management Corp CT ADV acquired a new stake in Repligen during the third quarter worth about $37,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.